AvantGen, Inc., a biotechnology company with its array of technology platforms for antibody discovery, optimization, and novel NK cell engager generation, today announced a strategic collaboration with an undisclosed biopharmaceutical company for the purpose of generating multiple novel bi-specific NK cell engaging therapeutic antibody product candidates.
Under the terms of the agreement, AvantGen will be responsible for engineering bi-specific variants of specified molecules using its proprietary NK cell engager platform and the biopharmaceutical company’s antibodies against a novel disease target. The biopharmaceutical company will receive worldwide rights on an exclusive basis with respect to its proprietary target to develop and commercialize product candidates arising from the collaboration. AvantGen receives upfront payments and is eligible to receive milestone payments and royalties associated with the development and sale of any products derived from the collaboration.
